With GLP-1 receptor agonists dominating headlines, researchers are now turning attention to other members of the glucagon-like peptide family. GLP-3 represents an underexplored but scientifically intriguing peptide fragment that may hold its own unique research value.
The Glucagon-Like Peptide Family
The glucagon-like peptides are derived from a single precursor protein: proglucagon. In pancreatic alpha cells, it produces glucagon. In intestinal L-cells and neurons, it produces GLP-1, GLP-2, and other fragments including GLP-3. GLP-1 is the well-known incretin hormone behind semaglutide and tirzepatide, demonstrating 7–24% body weight reductions in trials. GLP-2 promotes intestinal epithelium repair (teduglutide is FDA-approved for short bowel syndrome).
What Is GLP-3?
GLP-3 refers to a proglucagon-derived peptide fragment encompassing amino acids 126–158 of proglucagon (in humans), sitting downstream of GLP-2 in the sequence. It is co-secreted with GLP-1 and GLP-2 from intestinal L-cells in response to nutrient ingestion — particularly fats and carbohydrates.
Mechanisms of Action
Research on GLP-3 is less mature than for GLP-1 or GLP-2, but several insights have emerged. GLP-3 may play a role in intestinal motility regulation and mucosal signaling. Because it shares structural homology with GLP-1 and GLP-2, researchers hypothesize it may interact with related receptor systems — though it does not appear to have high affinity for the canonical GLP-1 receptor. Whether it acts through a distinct receptor or modulates GLP-1 signaling is an active area of inquiry.
GLP-3 vs. GLP-1
| Feature | GLP-1 | GLP-3 |
|---|---|---|
| Primary receptor | GLP-1R (well characterized) | Not fully established |
| Clinical drugs | Semaglutide, tirzepatide | None approved |
| Research maturity | Extensive human trial data | Preclinical and early-stage |
Why GLP-3 Research Is Gaining Momentum
The extraordinary success of GLP-1 therapeutics has prompted researchers to explore the broader proglucagon family. GLP-3’s gut origin suggests potential applications in mucosal integrity and inflammatory bowel disease pathways. If GLP-3 acts through a distinct receptor, it could represent an entirely new pharmacological target — potentially without the nausea and GI side effects of GLP-1 agonists. As of 2025–2026, research is identifying GLP-3 receptor targets, mapping secretion kinetics, and assessing its interaction with GLP-1/GLP-2 signaling.
Conclusion
GLP-3 sits at the frontier of proglucagon biology. Whether it emerges as a therapeutic target or a modulator of GLP-1/GLP-2 signaling, the next few years of research promise to be revealing. Combat Research supplies research-grade peptides for qualified applications, third-party tested for purity.
For research purposes only. Not intended for human therapeutic use.
Related Research Articles
- Semaglutide Research: Beyond Weight Loss
- AOD-9604: Weight Loss Peptide Fragment
- Peptide Stacking Guide
Shop GLP-3 at Combat Research
Combat Research carries research-grade GLP-3 in multiple sizes. ≥99% purity, USA domestic sourcing.
